Author

M. P. Mule

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

A. D. Sung· 1 shared A. J. Martins· 1 shared A. Lee· 1 shared A. Mammen· 1 shared A. Rajan· 1 shared B. Gerristen· 1 shared B. Pulendran· 1 shared C. B. DeStefano· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. Sung

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment

C. Zhao, M. P. Mule, A. J. Martins, I. Pinal-Fernandez, R. N. Donahue, J. Chen, J. Schlom, J. L. Gulley, A. Mammen, J. S. Tsang, A. Rajan

The paper identifies pre-treatment immune signatures associated with immune-related adverse events (irAEs) in thymic cancer patients receiving checkpoint inhibitors using CITE-seq.

bioRxiv · Jun 5, 2022 · PreprintImmunology

Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses

T. Hagan, B. Gerristen, L. E. Tomalin, S. Fourati, M. P. Mule, D. G. Chawla, D. Rychkov, E. Henrich, H. E. Miller, J. Diray-Arce, P. Dunn, A. Lee, The Human Immunology Project Consortium (HIPC), O. Levy, R. Gottardo, , B. Pulendran

The paper integrates transcriptional data from 13 vaccines to identify a time-adjusted signature predicting antibody responses across different vaccines.

bioRxiv · Apr 20, 2022Immunology

Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response

H. Y. Wong, A. D. Sung, K. E. Lindblad, S. Sheela, G. W. Roloff, D. Rizzieri, M. Goswami, M. P. Mule, N. R. Ramos, J. Tang, J. Thompson, C. B. DeStefano, K. Romero, L. W. Dillon, D.-Y. Kim, , C. S. Hourigan

This study evaluates molecular residual disease in AML patients during chemotherapy, finding stable variant allele frequencies that may indicate limited therapeutic response.

bioRxiv · Sep 20, 2018Cancer Biology